43 results on '"Duvic M."'
Search Results
2. Radiotherapy in the Treatment of Primary Cutaneous CD4+ Small/Medium T-Cell Lymphoproliferative Disorder
3. 851 Cancer associated fibroblasts in different T-stage lesions of cutaneous T-cell lymphoma
4. Concurrent Radiation Therapy With the Antibody-Drug Conjugates Brentuximab Vedotin and Polatuzumab Vedotin
5. 069 Oncogenic JAK3 mRNA isoform in cutaneous T-cell lymphoma
6. 589 Effects of CCR4 antagonists in cutaneous T-cell lymphoma cells
7. 393 Rare genetic mutations identify extracellular matrix genes as a contributing factor in alopecia areata etiology
8. 1022 Detection of copy number variation and gene mutation in cell-free DNA of patients with cutaneous T-cell lymphoma
9. Corrections to “Global patterns of care in advanced stage mycosis fungoides/Sezary syndrome: a multicenter retrospective follow-up study from the Cutaneous Lymphoma International Consortium”
10. Efficacy of mogamulizumab in previously treated patients with less advanced mycosis fungoides (MF): results from the MAVORIC study
11. Immunothérapie ciblée des lymphomes T cutanés par IPH4102, un anticorps monoclonal « first-in-class » dirigé contre la molécule KIR3DL2 : étude de phase I internationale multicentrique
12. Successful Suppression of Recurrent Zosteriform Mycosis Fungoides With Maintenance Valacyclovir
13. Supresión de un cuadro de micosis fungoide recurrente con distribución zosteriforme mediante tratamiento de mantenimiento con valaciclovir
14. Updated combined analysis of two phase II studies of brentuximab vedotin in patients with mycosis fungoides and Sézary syndrome
15. 459 Anti-CCR4 monoclonal antibody, mogamulizumab (Moga), demonstrates superior efficacy compared to vorinostat (Vor) in patients with previously treated cutaneous T-cell lymphoma (CTCL): results of the phase 3 MAVORIC study
16. 157 C1014T single nucleotide polymorphism of CCR4 is frequent in caucasian patients with cutaneous T-cell lymphoma
17. 170 Gene expression profiling and immune cell-type deconvolution highlight robust disease progression and survival markers in multiple cohorts of CTCL patients
18. 607 Anti-pruritic properties of remetinostat (SHAPE), a topical histone deacetylase inhibitor (HDACi); data from a randomized phase 2 study in patients with stage IA- IIA mycosis fungoides
19. Global patterns of care in advanced stage mycosis fungoides/Sezary syndrome: a multicenter retrospective follow-up study from the Cutaneous Lymphoma International Consortium
20. 052 Identification of pathogenic T cell subsets in human alopecia areata
21. 262 Brentuximab vedotin demonstrates superior activity to standard therapy in CD30-expressing (CD30+) cutaneous T-cell lymphoma (CTCL) in the randomized phase 3 ALCANZA study
22. 654 Monitoring malignant T-cell clones by direct TCR expression assay in patients with leukemic cutaneous T-cell lymphoma over extracorporeal photopheresis
23. CD4:CD8 Ratio in Mycosis Fungoides: Prognostic and Predictive Value of Circulating T Lymphocyte Subsets for Outcomes After Total Skin Electron Beam Radiation
24. Effectiveness of Very Low- and Low-Dose Radiation for Primary Cutaneous Anaplastic Large Cell Lymphoma
25. 399 Expression quantitative trait loci (eQTL) mapping in a multicenter cross-sectional study of Alopecia Areata
26. 029 CD209 + monocyte-derived myeloid dendritic cells were increased in patients with leukemic cutaneous T-cell lymphoma after extracorporeal photopheresis
27. 243 Pooled analyses of two phase II trials of Brentuximab vedotin in patients with Mycosis Fungoides (MF) and Sézary Syndrome (SS)
28. 006 Correlation between frequency of circulating lesional T cell clones and disease severity in human Alopecia Areata
29. 183 Cutaneous lymphoma international consortium (CLIC): Uniting worldwide experts to develop and validate a prognostic index model
30. Allogeneic stem-cell transplantation in patients with cutaneous lymphoma: updated results from a single institution
31. Low Dose (12 Gy) Total Skin Electron Beam Therapy (TSEBT) for Mycosis Fungoides (mf): Results of Three Phase 2 Clinical Trials
32. Final results of a multicenter phase II study of the purine nucleoside phosphorylase (PNP) inhibitor forodesine in patients with advanced cutaneous t-cell lymphomas (CTCL) (Mycosis fungoides and Sézary syndrome)
33. Final results of phase II trial of doxorubicin HCl liposome injection followed by bexarotene in advanced cutaneous T-cell lymphoma
34. A cutaneous lymphoma international prognostic index (CLIPi) for mycosis fungoides and Sezary syndrome
35. Novel treatments for cutaneous T-cell lymphomas
36. Alopecia areata after allogeneic bone marrow transplantation from an affected, human leukocyte antigen–matched sibling
37. Interleukin-10 levels are often elevated in serum of adults with Hodgkin's disease and are associated with inferior failure-free survival
38. Pivotal phase III trial of two dose levels of DAB389IL-2 (ontak™) for the treatment of cutaneous T-cell lymphoma (CTCL)
39. Epidermal surface antigen (ESA) is distinct from ECS-1 antigen and confers a dendritic phenotype to cos cells
40. Long-range amplification of genomic DNA detects the t(2;5)(p23;q35) in anaplastic large-cell lymphoma, but not in other non-Hodgkin's lymphomas, Hodgkin's disease, or lymphomatoid papulosis
41. Cloning and characterization of a novel epidermal cell surface antigen (ESA).
42. Exclusion of candidate genes in Darier's disease using positional cloning
43. Myogenin is in an evolutionarily conserved linkage group on human chromosome 1q31–q41 and unlinked to other mapped muscle regulatory factor genes
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.